CONNECT WITH US
Web3 & Blockchain

Web3 & Blockchain

OpenAI acquires Orchestra Bio to expand life sciences AI

Blockchain.News logo

Published on

Add as a preferred source on Google
OpenAI acquires Orchestra Bio to expand life sciences AI

OpenAI said on Oct. 20, 2026, it acquired Orchestra Bio and will combine the team and technology with its Rosalind life-sciences AI platform.

OpenAI said it has acquired Orchestra Bio, a move it says will bring AI-powered operations into life sciences research and development and help biopharma teams accelerate drug development and advance new treatments.

In its Oct. 20, 2026 announcement, OpenAI said Orchestra Bio’s team and technology will be combined with Rosalind, OpenAI’s life-sciences AI platform. The company did not provide financial terms in the material supplied. The acquisition is positioned around operational workflows in drug development rather than consumer-facing AI products.

Background material supplied with the announcement describes Orchestra Bio as software for biotechnology and pharmaceutical teams that supports study monitoring, timeline tracking, dependency analysis and operational planning through AI agents, while keeping decision-making with humans. A BiotechTV interview published on Aug. 18, 2025 said the company had emerged from stealth with $20 million, though that publication date is not the original financing date. Separately, MBC BioLabs said on Nov. 4, 2025 that it had partnered with Orchestra Bio to support its community of biotech startups.

Orchestra Bio should not be confused with Orchestra BioMed Holdings, the separate Nasdaq-listed medical-device company trading under OBIO. No next catalyst date was supplied in the source material.

Enter your email and choose your email permissions in a new window.



Source link
Related Topics:Web3 & Blockchain

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.